The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia



      To examine whether genetic polymorphisms in the cholesteryl-ester transfer protein (CETP) and the P-glycoprotein drug transporter (MDR1), are associated with variable lipid response to fluvastatin.


      Lipid levels were determined in a compliance-monitored clinical study at baseline and following 20 weeks of treatment with 40 mg dose of fluvastatin in 76 FH patients. CETP and MDR1 SNP genotyping was performed and linear regression was used to examine the associations between common SNPs and haplotypes and lipid response.


      Treatment with 40 mg of fluvastatin resulted in mean low density lipoprotein cholesterol (LDL-C) reduction of 21.5%; mean triglyceride (TG) reduction of 8.3%; and a mean high-density lipoprotein cholesterol (HDL-C) increase of 13.4%. Five tagging SNPs in both genes were used to reconstruct five and six haplotypes accounting for 71.4% and 90.2% of the observed haplotypes in the CETP and MDR1 genes, respectively. CETP-H13 and MDR1-h4 were associated with an increase in LDL-C response. CETP-H5 was significantly associated with decreased TG and HDL-C response, whereas MDR1-h10 was associated with decreased TG response. A multivariate regression model indicated an independent additive effect of CETP-H5 and MDR1-h10 on the level of TG response.


      CETP and MDR1 have independent effects on lipid changes following fluvastatin treatment. The results of this study may lead to an improved understanding of the genetic determinants of lipids response to treatment.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
        Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
        N Engl J Med. 1998; 339: 1349-1357
        • Pearson T.A.
        • Laurora I.
        • Chu H.
        • Kafonek S.
        The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.
        Arch Intern Med. 2000; 160: 459-467
        • Evans W.E.
        • Johnson J.A.
        Pharmacogenomics: the inherited basis for interindividual differences in drug response.
        Annu Rev Genomics Hum Genet. 2001; 2: 9-39
        • Levêque D.
        • Jehl F.
        P-glycoprotein and pharmacokinetics.
        Anticancer Res. 1995; 15: 331-336
        • Fellay J.
        • Marzolini C.
        • Meaden E.R.
        • et al.
        Swiss HIV Cohort Study response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.
        Lancet. 2002; 359: 30-36
        • Bogman K.
        • PeyerAK
        • Torok M.
        • Kusters E.
        • Drewe J.
        HMG-CoA reductase inhibitors and P-glycoprotein modulation.
        Br J Pharmacol. 2001; 132: 1183-1192
        • Kajinami K.
        • Brousseau M.E.
        • Ordovas J.M.
        • Schaefer E.J.
        Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to Atorvastatin treatment in a gender-specific manner.
        Am J Cardiol. 2004; 93: 1046-1050
        • Williams D.
        • Feely J.
        Pharmacokinetic–pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
        Clin Pharmacokinet. 2002; 41: 343-370
        • Kirchheiner J.
        • Kudlicz D.
        • Meisel C.
        • et al.
        Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (−)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
        Clin Pharmacol Ther. 2003; 74: 186-194
        • Kuivenhoven J.A.
        • Jukema J.W.
        • Zwinderman A.H.
        • et al.
        The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis.
        N Engl J Med. 1998; 338: 86-93
        • Bruce C.
        • Tall A.R.
        Cholesteryl ester transfer protein, reverse cholesterol transport and atherosclerosis.
        Curr Opin Lipidol. 1995; 6: 306-311
        • Brown M.L.
        • Inazu A.
        • Hesler C.B.
        • et al.
        Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins.
        Nature. 1989; 342: 448-451
        • Koizumi J.
        • Mabuchi H.
        • Yoshimura A.
        • et al.
        Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia.
        Atherosclerosis. 1985; 58: 175-186
        • Ikewaki K.
        • Nishiwaki M.
        • Sakamoto T.
        • et al.
        Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency.
        J Clin Invest. 1995; 96: 1573-1581
        • Kuivenhoven J.A.
        • de Knijff P.
        • Boer J.M.A.
        • et al.
        Heterogeneity at the CETP gene locus: influence on plasma CETP concentrations and HDL cholesterol levels.
        Arterioscler Thromb Vasc Biol. 1997; 17: 560-568
        • Bruce C.
        • Sharp D.S.
        • Tall A.R.
        Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia.
        J Lipid Res. 1998; 39: 1071-1078
        • Bernard S.
        • Moulin P.
        • Lagrost L.
        • et al.
        Association between plasma HDL-cholesterol concentration and TaqIB CETP gene polymorphism in non-insulin-dependent diabetes mellitus.
        J Lipid Res. 1998; 39: 59-65
        • Dachet C.
        • Poirier O.
        • Cambien F.
        • Chapman J.
        • Rouis M.
        New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high-density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation.
        Arterioscler Thromb Vasc Biol. 2000; 20: 507-515
        • Kawasaki I.
        • Tahara H.
        • Emoto M.
        • Shoji T.
        • Nishizawa Y.
        Relationship between TaqIB cholesteryl ester transfer protein gene polymorphism and macrovascular complications in Japanese patients with type 2 diabetes.
        Diabetes. 2002; 51: 871-874
        • van Venrooij F.V.
        • Stolk R.P.
        • Banga J.D.
        • et al.
        Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes.
        Diab Care. 2003; 26: 1216-1223
        • Winkelmann B.R.
        • Hoffmann M.M.
        • Nauck M.
        • et al.
        Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy.
        Pharmacogenomics J. 2003; 3: 284-296
        • Goldstein J.L.
        • Hobbs H.H.
        • Brown M.S.
        Familial hypercholesterolemia.
        in: Scriver S.R. Beaudet A.L. Valle D. Sly W.S. Childs B. Kinzler K.W. Vogelstein B. The metabolic and molecular bases of inherited disease. McGraw-Hill, New York2001: 2863-2913
        • Reshef A.
        • Nissen H.
        • Triger L.
        • et al.
        Molecular genetics of familial hypercholesterolemia in Israel.
        Hum Genet. 1996; 98: 581-586
      1. National Cholesterol Education Program. Report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Washington, DC: US Department of Health and Human Services; 1993.

        • Friedewald W.T.
        • Levy R.I.
        • Fredrickson D.S.
        Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • Bodamer O.A.
        • Bercovich D.
        • Schlabach M.
        • et al.
        Use of denaturing HPLC to provide efficient detection of mutations causing familial hypercholesterolemia.
        Clin Chem. 2002; 48: 1913-1918
        • Carlson C.S.
        • Eberle M.A.
        • Rieder M.J.
        • et al.
        Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium.
        Am J Hum Genet. 2004; 74: 106-120
        • Stephens M.
        • Smith N.J.
        • Donnelly P.
        A new statistical method for haplotype reconstruction from population data.
        Am J Hum Genet. 2001; 68: 978-989
        • Snedecor G.W.
        • Cochran W.G.
        Statistical methods.
        Iowa State University Press, Ames1980
        • Burt R.D.
        • Vaughan T.L.
        • McKnight B.
        • et al.
        Associations between human leukocyte antigen type and nasopharyngeal carcinoma in Caucasians in the United States.
        Cancer Epidemiol Biomarkers Prev. 1996; 5: 879-887
        • Edgington E.S.
        Randomization tests.
        Marcel Deckker Inc., New York1995
        • Carlquist J.F.
        • Muhlestein J.B.
        • Horne B.D.
        • et al.
        The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease.
        Am Heart J. 2003; 146: 1007-1014
        • de Grooth G.J.
        • Zerba K.E.
        • Huang S.P.
        • et al.
        The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.
        J Am Coll Cardiol. 2004; 43: 854-857
        • Brousseau M.E.
        • Schaefer E.J.
        • Wolfe M.L.
        • et al.
        Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
        N Engl J Med. 2004; 350: 1505-1515
        • Kirchheiner J.
        • Kudlicz D.
        • Meisel C.
        • et al.
        Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (−)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
        Clin Pharmacol Ther. 2003; 74: 186-194
        • van Helvoort A.
        • Smith A.J.
        • Sprong H.
        • et al.
        MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine.
        Cell. 1996; 87: 507-517
        • Raggers R.J.
        • van Helvoort A.
        • Evers R.
        • van Meer G.
        The human multidrug resistance protein MRP1 translocates sphingolipid analogs across the plasma membrane.
        J Cell Sci. 1999; 112: 415-422
        • Kwong M.
        • Wasan K.M.
        Cholesteryl ester transfer protein facilitates the movement of water-insoluble drugs between lipoproteins: a novel biological function for a well-characterized lipid transfer protein.
        Biochem Pharmacol. 2002; 64: 1669-1675